DCGI approves psoriasis injection for restricted emergency use on COVID-19 patients

Representational image

The Drug Controller General of India (DCGI) has approved Itolizumab injection, a drug to cure psoriasis, for the restricted emergency use on COVID-19 patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS) due to virus.

The top drug regulator, Dr VG Somani on Friday gave his green signal for Itolizumab injection–a recombinant anti-CD6 monoclonal antibody for the restricted emergency use on COVID-19 patients with moderate to severe Acute Respiratory Distress Syndrome (ARDS).

Itolizumab injection is already approved drug of Biocon Ltd used for the treatment of patients with active moderate to severe chronic plaque psoriasis for the last many years.

ALSO READ: COVID-19 LIVE | With record 27,114 new cases in 24 hrs, India’s tally tops 8.20 lakh

“After clinical trials on coronavirus patients in India, the drug was found satisfactory by the subject expert committee consisting of pulmonologist, pharmacologist, medicine experts from AIIMS etc and it is cleared for restricted emergency use for the treatment of cytokine release syndrome (CRS) on COVID-19 patients with moderate to severe acute respiratory distress syndrome (ARDS),” said the official.

Doctors have to get the consent-form duly filled by the patient in a prescribed manner before using the drug.

Besides this, the pharma company i.e. Biocon Ltd has to follow up each and every patient’s case with regard to safety and efficacy of the drug to whom this drug is being administered, said the official adding that the pharma company has to conduct the post-marketing trial etc.

Click here for Latest News updates and viral videos on our AI-powered smart news

For viral videos and Latest trends subscribe to NewsMobile YouTube Channel and Follow us on Instagram

LEAVE A REPLY

Please enter your comment!
Please enter your name here